Trial Profile

An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canakinumab (Primary) ; Canakinumab (Primary) ; Prednisolone
Indications Behcet's syndrome
Focus Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
28 May 2020 Status changed from recruiting to completed.
17 Jan 2019 Planned End Date changed from 25 Jun 2018 to 12 Feb 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com